Payment overview · 2025
General Payments
$220.79
15 reported records · 5 companies
Healthcare provider profile · identity verified
Daniel Naul
Allopathic & Osteopathic Physicians|Family Medicine · BATON ROUGE, LA · NPI 1003234915
Verified facts
What the public records show
CMS Open Payments records show Daniel Naul received $220.79 in general payments during 2025 across 15 reported records.
GlaxoSmithKline, LLC. accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Shingrix, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.57 | 35.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.38 | 23.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.56 | 16.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.38 | 15.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.90 | 9.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $220.79 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.72 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.38 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.90 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
35 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 525 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 461 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 117 |
| Alprazolam | Alprazolam | 439 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 108 |
| Metformin Hcl | Metformin Hcl | 411 | 118 |
| Lisinopril | Lisinopril | 391 | 108 |
| Doxycycline Hyclate | Doxycycline Hyclate | 307 | 242 |
| Gabapentin | Gabapentin | 255 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 237 | 73 |
| Omeprazole | Omeprazole | 220 | 66 |
| Losartan Potassium | Losartan Potassium | 217 | 67 |
| Sertraline Hcl | Sertraline Hcl | 212 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 211 | 54 |
| Prednisone | Prednisone | 206 | 175 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 46 |
| Montelukast Sodium | Montelukast Sodium | 175 | 65 |
| Ozempic | Semaglutide | 174 | 29 |
| Carvedilol | Carvedilol | 161 | 52 |
| Furosemide | Furosemide | 156 | 59 |
| Trazodone Hcl | Trazodone Hcl | 155 | 44 |
| Simvastatin | Simvastatin | 153 | 45 |
| Azithromycin | Azithromycin | 152 | 133 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 150 | 123 |
| Cephalexin | Cephalexin | 150 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 36 |
| Allopurinol | Allopurinol | 131 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 24 |
| Meloxicam | Meloxicam | 124 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 29 |
| Glimepiride | Glimepiride | 115 | 42 |
| Amoxicillin | Amoxicillin | 104 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 26 |
| Clonazepam | Clonazepam | 98 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 26 |
| Cefdinir | Cefdinir | 91 | 84 |
| Alendronate Sodium | Alendronate Sodium | 90 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 63 |
| Mupirocin | Mupirocin | 87 | 74 |
| Ezetimibe | Ezetimibe | 85 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 21 |
| Januvia | Sitagliptin Phosphate | 83 | 16 |
| Tramadol Hcl | Tramadol Hcl | 83 | 41 |
| Jardiance | Empagliflozin | 81 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 64 |
| Eliquis | Apixaban | 77 | 20 |
| Dexamethasone | Dexamethasone | 74 | 71 |
| Ondansetron Odt | Ondansetron | 72 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 55 |
| Fluconazole | Fluconazole | 66 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 38 |
| Potassium Chloride | Potassium Chloride | 65 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 14 |
| Lorazepam | Lorazepam | 60 | 11 |
| Mirtazapine | Mirtazapine | 60 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 17 |
| Bupropion Xl | Bupropion Hcl | 55 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 37 |
| Naproxen | Naproxen | 52 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 13 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 47 | 36 |
| Nifedipine Er | Nifedipine | 47 | 16 |
| Fenofibrate | Fenofibrate | 46 | 13 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 12 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 27 |
| Irbesartan | Irbesartan | 39 | 11 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Atenolol | Atenolol | 38 | 13 |
| Levofloxacin | Levofloxacin | 38 | 34 |
| Estradiol | Estradiol | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Finasteride | Finasteride | 33 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 31 | suppressed |
| Lactulose | Lactulose | 31 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 25 |
| Diazepam | Diazepam | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | 14 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Temazepam | Temazepam | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 15 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 19 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 16 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 14 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $220.79 · 15 records | GlaxoSmithKline, LLC. | AREXVY, JARDIANCE, NURTEC ODT, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error